Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

被引：1
|
作者：
Duvic, M.
Vanaclocha, F.
Bernengo, M. G.
Okada, C.
Breneman, D.
Zinzani, P. L.
Zhang, L.
Bopp, K.
Laird, G.
Hirawat, S.
Prince, M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Turin, Turin, Italy
[3] Portland VA Med Ctr, Portland, OR USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Ist Ematol Oncol Med, Bologna, Italy
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8555
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, Amy Patricia
    Thach-Giao Truong
    Thurn, Kenneth Ted
    Thomas, Scott
    Ryan, Charles J.
    Jahan, Thierry Marie
    DuBois, Steven G.
    Chan, John K.
    Rugo, Hope S.
    Collisson, Eric Andrew
    Raha, Paromita
    Chen, Stephanie
    Reinert, Anne
    Daud, Adil
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin gene expression profiles in the first 24 hours related to clinical response following therapy.
    Prince, Miles
    George, D. J.
    Johnstone, R.
    McCormack, C.
    Ellis, L.
    Williams-Truax, R.
    Atadja, P.
    Zhao, C.
    Dugan, M.
    Culver, K.
    BLOOD, 2006, 108 (11) : 767A - 767A
  • [33] Phase I/II study of oral fodosine™, a PNP inhibitor in refractory cutaneous T-cell lymphoma patients
    Duvic, M
    Breneman, D
    Cooper, M
    Fonseca, G
    Bennett, JC
    Kilpatrick, JM
    Bantia, S
    BLOOD, 2005, 106 (11) : 753A - 753A
  • [34] A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Spencer, A.
    Taylor, K.
    Lonial, S.
    De la Rubia, J.
    Facon, T.
    Bengoudifa, R.
    Klebsattel, M.
    Hazell, K.
    Bourquelot, P.
    Rossi, J. F.
    Harousseau, J. L.
    Jagannath, S.
    Wolf, J.
    San Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 158 - 158
  • [35] Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies
    Spencer, Andrew
    Prince, Miles
    DeAngelo, Daniel J.
    Fischer, Thomas
    Bhalla, Kapil N.
    Giles, Francis J.
    Liu, Angela
    Parker, Kathryn
    Laird, Glen
    Masson, Eric
    Rediske, John
    Scott, Jeffrey W.
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (11) : 276A - 277A
  • [36] Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
    Wolf, Jeffrey L.
    Siegel, David
    Goldschmidt, Hartmut
    Hazell, Katharine
    Bourquelot, Priscille M.
    Bengoudifa, Bourras R.
    Matous, Jeffrey
    Vij, Ravi
    de Magalhaes-Silverman, Margarida
    Abonour, Rafat
    Anderson, Kenneth C.
    Lonial, Sagar
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1820 - 1823
  • [37] Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Shi, Yuankai
    Dong, Mei
    Zhu, Jun
    Zhou, Daobin
    Huang, Huiqiang
    Tu, Ping
    Zhang, Weijing
    Hong, Xiaonan
    Zhao, Xielan
    Sun, Jianfang
    Liu, Yuehua
    Qiu, Lugui
    Shen, ZhiXiang
    Feng, Jifeng
    Ke, Xiaoyan
    BLOOD, 2015, 126 (23)
  • [38] A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    DeJonge, M.
    Woo, M. M.
    Van der Biessen, D.
    Hamberg, P.
    Sharma, S.
    Chen, L. C.
    Myke, N.
    Zhao, L.
    Hirawat, S.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma
    Wada, Hidefumi
    Tsuboi, Ryoji
    Kato, Yukihiko
    Sugaya, Makoto
    Tobinai, Kensei
    Hamada, Toshihisa
    Shimamoto, Takashi
    Noguchi, Kazuo
    Iwatsuki, Keiji
    JOURNAL OF DERMATOLOGY, 2012, 39 (10): : 823 - 828
  • [40] Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT)
    Sureda, A.
    Engert, A.
    Browett, P. J.
    Radford, J. A.
    Verhoef, G. E.
    Ramchandren, R.
    Myke, N.
    Shen, A.
    Le Corre, C.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345